AU2001259303A1 - Glycopeptide carboxy-saccharide derivatives - Google Patents

Glycopeptide carboxy-saccharide derivatives

Info

Publication number
AU2001259303A1
AU2001259303A1 AU2001259303A AU5930301A AU2001259303A1 AU 2001259303 A1 AU2001259303 A1 AU 2001259303A1 AU 2001259303 A AU2001259303 A AU 2001259303A AU 5930301 A AU5930301 A AU 5930301A AU 2001259303 A1 AU2001259303 A1 AU 2001259303A1
Authority
AU
Australia
Prior art keywords
glycopeptide
carboxy
saccharide derivatives
glycopeptide derivatives
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259303A
Inventor
Paul R. Fatheree
J. Kevin Judice
Michael R. Leadbetter
Martin S. Linsell
Yan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AU2001259303A1 publication Critical patent/AU2001259303A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are glycopeptide derivatives substituted at the C-terminus and/or the R-terminus with a substituent that comprises one or more saccharide groups and a carboxy group; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
AU2001259303A 2000-06-22 2001-05-01 Glycopeptide carboxy-saccharide derivatives Abandoned AU2001259303A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21341700P 2000-06-22 2000-06-22
US60213417 2000-06-22
PCT/US2001/013996 WO2001098327A2 (en) 2000-06-22 2001-05-01 Glycopeptide carboxy-saccharide derivatives

Publications (1)

Publication Number Publication Date
AU2001259303A1 true AU2001259303A1 (en) 2002-01-02

Family

ID=22795046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259303A Abandoned AU2001259303A1 (en) 2000-06-22 2001-05-01 Glycopeptide carboxy-saccharide derivatives

Country Status (7)

Country Link
US (4) US6620781B2 (en)
EP (1) EP1292611B1 (en)
AT (1) ATE388960T1 (en)
AU (1) AU2001259303A1 (en)
DE (1) DE60133198T2 (en)
ES (1) ES2302733T3 (en)
WO (1) WO2001098327A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770621B2 (en) * 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
CN1223378C (en) * 2000-05-02 2005-10-19 施万制药 Cyclodextrin containing glycopeptide antibiotic pharmaceutical compositions
CN100532392C (en) * 2000-05-02 2009-08-26 施万制药 Reductive alkylation process
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (en) * 2000-06-22 2008-08-01 Theravance, Inc. CARBOXI-SACARIDS DERIVATIVES OF GLUCOPEPTIDE.
UA75083C2 (en) 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
BRPI0206747B1 (en) * 2001-01-25 2017-03-21 Luminex Molecular Diagnostics Inc polynucleotides for use as labels and tag complements, manufacture and use thereof
WO2008118784A1 (en) * 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility
JP2010095454A (en) * 2008-10-14 2010-04-30 Cyclochem:Kk Antibacterial composition
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
WO2011019839A2 (en) * 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
EP3049115A1 (en) 2013-09-23 2016-08-03 Jawaharlal Nehru Centre For Advanced Scientific Research Vancomycin-sugar conjugates and uses thereof
CN107325159A (en) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 One class vancomycin derivatives, its preparation method, pharmaceutical composition and purposes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55464A (en) * 1866-06-12 Improved mode of starting cars
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
WO1994012217A1 (en) 1992-12-02 1994-06-09 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
UA43323C2 (en) 1994-01-28 2001-12-17 Елі Ліллі Енд Компані Glycopeptide antibiotic derivatives, process for preparation and pharmaceutical composition
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
JPH11113593A (en) * 1997-09-17 1999-04-27 Noguchi Inst New complex glycopeptide and its production and intermediate therefor
NZ509165A (en) 1998-07-14 2003-08-29 Univ Princeton Glycopeptide antobiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
CA2336445C (en) * 1998-12-23 2011-07-19 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (en) 1999-03-12 2000-09-14 Basf Ag Process for the preparation of solid dosage forms containing cyclodextrin
US6518243B1 (en) 1999-04-02 2003-02-11 Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
US6770621B2 (en) * 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
BR0112393A (en) 2000-06-21 2003-07-08 Internat Health Man Associates Compositions and processes for improving oral absorption of antimicrobial agents
AU2001259302A1 (en) 2000-06-22 2002-01-02 Yongqi Mu Glycopeptide disulfide and thioester derivatives
UA75083C2 (en) 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
ES2302733T3 (en) * 2000-06-22 2008-08-01 Theravance, Inc. CARBOXI-SACARIDS DERIVATIVES OF GLUCOPEPTIDE.
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives

Also Published As

Publication number Publication date
US20020028770A1 (en) 2002-03-07
US20070042942A1 (en) 2007-02-22
EP1292611B1 (en) 2008-03-12
DE60133198D1 (en) 2008-04-24
US6903070B2 (en) 2005-06-07
ES2302733T3 (en) 2008-08-01
US20050159344A1 (en) 2005-07-21
US6620781B2 (en) 2003-09-16
US7157554B2 (en) 2007-01-02
DE60133198T2 (en) 2009-03-12
ATE388960T1 (en) 2008-03-15
US7265086B2 (en) 2007-09-04
US20040087494A1 (en) 2004-05-06
WO2001098327A2 (en) 2001-12-27
WO2001098327A3 (en) 2002-04-04
EP1292611A2 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
HRP20020888A2 (en) Glycopeptide phosphonate derivatives
AU2001239725A1 (en) Antibacterial agents
IL140093A0 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
AU2003303458A1 (en) Ampholytic copolymer and use thereof
AU781269C (en) Pharmaceutical compositions
DE69716135T2 (en) IN 6-POSITION BY THIO SUBSTITUTED PACLITAXELE
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2001259303A1 (en) Glycopeptide carboxy-saccharide derivatives
AU4155897A (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
AU1735001A (en) Cyclodextrin-containing pharmaceutical composition
AU9534398A (en) Novel pharmaceutical composition
WO2001083520A3 (en) Polyacid glycopeptide derivatives
AU2001273919A1 (en) Pharmaceutical compositions
AU2881399A (en) N1-modified glycopeptides
AU4925200A (en) Oral composition containing perlite
AU6849198A (en) Neurotrypsin
AU4085201A (en) Pharmaceutical composition
WO2002057281A3 (en) Aminoglycosides as antibiotics
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
WO2001098326A3 (en) Glycopeptide disulfide and thioester derivatives
AU7655600A (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one
AU2001278705A1 (en) Pharmaceutical composition
AU2003275360A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents